Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

Outlook Reflects a Net Negative Impact of $0.24 per Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi Sankyo Merck (NYSE: MRK), known as MSD outside the ...

Merck & Co. Inc.’s stock swung between gains and losses premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, but lowered guidance due to deals with ...

Merck & Co. Inc.'s stock fell 3% Thursday ... stemming from deals with partners Curon Biopharmaceutical and Daiichi Sankyo. The Rahway, N.J.-based company (MRK) posted net income of $3.157 ...